Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib in Relapsed Acute Lymphoblastic Leukemia
NCT05137860Phase 4Unknown
- Sponsor
- Hospital General de México "Dr. Eduardo Liceaga"
- Start
- Dec 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of bortezomib in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Hospital General de México "Dr. Eduardo Liceaga". Primary endpoints: Survival Outcome at 3 months, Hospital stay at 3 months and 3 more. Status: unknown.
02
Drugs
bortezomib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT05137860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05137860.